Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Elsey (Manchester, United Kingdom), J. Wingfield-Derby (Manchester, United Kingdom), L. Holmes (Manchester, United Kingdom), L. Maguire (Manchester, United Kingdom), K. Newman (Manchester, United Kingdom), T. Pantin (Manchester, United Kingdom), S. Fowler (Manchester, United Kingdom). Severe asthma outcomes over 18-months treatment with mepolizumab, and comorbidities in non-responders.. 2256

Member's Comments

No comment yet.

Related content which might interest you: Severe asthma outcomes over two years of therapy with mepolizumab Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Outcomes over the first two years of treatment with mepolizumab in severe asthma Source: Eur Respir J, 58 (6) 2101313; 10.1183/13993003.01313-2021 Year: 2021 Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019 Year: 2020 A longitudinal follow-up of severe asthma patients receiving reslizumab Source: International Congress 2017 – Asthma management Year: 2017 Early treatment response may predict long-term mepolizumab benefit in severe asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study) Source: Eur Respir J, 59 (1) 2100396; 10.1183/13993003.00396-2021 Year: 2022 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Severe outcomes of COVID-19 among patients with COPD and asthma Source: ERJ Open Res, 7 (1) 00594-2020; 10.1183/23120541.00594-2020 Year: 2021 Patient-reported versus objective adherence and exacerbation rates in severe asthma. Source: Virtual Congress 2020 – Clinical parameters in severe asthma Year: 2020 Inflammatory biomarkers in the evaluation of two-year  outcomes  of omalizumab treatment in severe allergic asthma. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 194s Year: 2007 Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Exacerbations of severe asthma in patients treated with mepolizumab Source: Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018 Year: 2018 Symptom pattern and treatment for people non-compliant with asthma medication Source: Annual Congress 2005 - Allergic rhinitis and asthma in primary care Year: 2005 Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020